Related Experiment Video
Updated: Jun 17, 2025
11:20
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
6.5K
Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.
Mario Cocorullo1, Giovanni Stelitano1, Laurent Robert Chiarelli1
1Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy.
International Journal of Molecular Sciences
|August 10, 2024
Summary
Phage therapy offers a promising alternative to antibiotics for cystic fibrosis (CF) patients battling difficult lung infections. This approach uses viruses to target multi-drug resistant bacteria, addressing a critical need in CF care.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Bacteriophage Therapy
Background:
- Cystic fibrosis (CF) patients frequently suffer from severe lung infections caused by challenging pathogens like Pseudomonas aeruginosa and Staphylococcus aureus.
- Despite advancements in CF treatment, these infections persist and contribute to significant morbidity and mortality.
- Extensive antibiotic use in CF care accelerates the development of antimicrobial resistance, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the current landscape of phage therapy for multidrug-resistant infections in cystic fibrosis (CF) patients.
- To explore the potential of bacteriophages as an alternative treatment modality against CF-associated pathogens.
- To discuss the progression of phage therapy from compassionate use to clinical trials and identify associated challenges.
Main Methods:
- Literature review of existing studies on phage therapy in CF.
- Analysis of compassionate use cases and ongoing clinical trials.
- Examination of challenges specific to implementing phage therapy in CF patients.
Main Results:
- Phage therapy is emerging as a viable strategy for managing multidrug-resistant bacterial infections in CF.
- Case studies and early clinical trials show promise in eradicating difficult-to-treat pathogens.
- Significant challenges remain, including regulatory hurdles, phage resistance development, and optimal delivery methods for CF lung infections.
Conclusions:
- Phage therapy presents a promising avenue for combating multidrug-resistant infections in cystic fibrosis.
- Further research and well-designed clinical trials are essential to establish its efficacy and safety.
- Overcoming implementation challenges is key to integrating phage therapy into standard CF care.
Related Concept Videos
01:30Lytic Cycle of Bacteriophages
70.5K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.5K
01:24Cystic Fibrosis: Management
150
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
150
00:43Lysogenic Cycle of Bacteriophages
62.0K
In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
62.0K
01:23Cystic Fibrosis: Pathogenesis
201
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
201
01:30Acute Pharyngitis
528
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
528
01:28Pneumonia IV: Management
314
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
314